Jaguar Health (JAGX) Other Non-Current Liabilities (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Other Non-Current Liabilities of $187000.0 for Q1 2026, down 99.49% year-over-year from $37.0 million in Q1 2025, and down 99.41% quarter-over-quarter from $31.9 million in Q4 2025.
Jaguar Health (JAGX) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Other Non-Current Liabilities for 13 consecutive years, with $187000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 99.49% year-over-year to $187000.0; the TTM figure through Mar 2026 stood at $187000.0 (down 99.49% YoY), while the FY2025 annual figure was $31.9 million, down 9.77% from the prior year.
- Other Non-Current Liabilities slipped to $187000.0 in Q1 2026 per JAGX's latest filing, from $31.9 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $37.0 million in Q1 2025 and bottomed at $1000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $24.3 million across 5 years, with a median of $30.9 million in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 783800.0% — and 2026, when it plunged 99.49%.
- Jaguar Health's Other Non-Current Liabilities stood at $7.8 million in 2022, then jumped by 294.73% to $30.9 million in 2023, then rose by 14.26% to $35.4 million in 2024, then declined by 9.77% to $31.9 million in 2025, then sank by 99.41% to $187000.0 in 2026.
- Business Quant data shows JAGX's Other Non-Current Liabilities at $187000.0 in Q1 2026, $31.9 million in Q4 2025, and $30.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 187,000.00 |
| Dec 31, 2025 | 31.90 Mn |
| Sep 30, 2025 | 30.42 Mn |
| Jun 30, 2025 | 28.81 Mn |
| Mar 31, 2025 | 37.01 Mn |
| Dec 31, 2024 | 35.36 Mn |
| Sep 30, 2024 | 32.79 Mn |
| Mar 31, 2024 | 31.96 Mn |
| Dec 31, 2023 | 30.94 Mn |
| Dec 31, 2022 | 7.84 Mn |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | 7,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | 126,000.00 |
| Jun 30, 2020 | 4.09 Mn |
| Mar 31, 2020 | 1.25 Mn |
| Dec 31, 2019 | 1.50 Mn |